[go: up one dir, main page]

UA87515C2 - Фармацевтическая композиция толтеродина с пролонгированным высвобождением - Google Patents

Фармацевтическая композиция толтеродина с пролонгированным высвобождением

Info

Publication number
UA87515C2
UA87515C2 UAA200703260A UAA200703260A UA87515C2 UA 87515 C2 UA87515 C2 UA 87515C2 UA A200703260 A UAA200703260 A UA A200703260A UA A200703260 A UAA200703260 A UA A200703260A UA 87515 C2 UA87515 C2 UA 87515C2
Authority
UA
Ukraine
Prior art keywords
pharmaceutical composition
tolterodine
sustained release
release pharmaceutical
composition
Prior art date
Application number
UAA200703260A
Other languages
English (en)
Ukrainian (uk)
Inventor
Адрейка Крамер
Роберт Писек
Тадея Райер
Original Assignee
Крка, Д.Д. Ново Место
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34926332&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA87515(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Крка, Д.Д. Ново Место filed Critical Крка, Д.Д. Ново Место
Publication of UA87515C2 publication Critical patent/UA87515C2/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Данное изобретение относится к фармацевтической композиции с пролонгированным высвобождением, которая содержит толтеродин, преимущественно толтеродина тартрат, применения указанной композиции для приготовления лекарственного средства и способа получения такой фармацевтической композиции.
UAA200703260A 2004-08-27 2005-08-23 Фармацевтическая композиция толтеродина с пролонгированным высвобождением UA87515C2 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP04020431A EP1629834A1 (en) 2004-08-27 2004-08-27 Sustained release pharmaceutical composition of tolterodine

Publications (1)

Publication Number Publication Date
UA87515C2 true UA87515C2 (ru) 2009-07-27

Family

ID=34926332

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA200703260A UA87515C2 (ru) 2004-08-27 2005-08-23 Фармацевтическая композиция толтеродина с пролонгированным высвобождением

Country Status (7)

Country Link
EP (3) EP1629834A1 (ru)
AT (1) ATE505187T1 (ru)
DE (1) DE602005027469D1 (ru)
EA (1) EA200700484A1 (ru)
NO (1) NO20071299L (ru)
UA (1) UA87515C2 (ru)
WO (1) WO2006021425A1 (ru)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2645940A1 (en) * 2006-03-21 2007-09-27 Teva Pharmaceutical Industries Ltd. Controlled release formulation of tolterodine
EP1839649A1 (en) * 2006-03-31 2007-10-03 LEK Pharmaceuticals D.D. Coated formulations for tolterodine
KR100851033B1 (ko) * 2007-02-12 2008-08-12 명문제약주식회사 엘-주석산 톨터로딘 함유 서방성 제제의 제조방법
WO2009019599A2 (en) * 2007-08-08 2009-02-12 Themis Laboratories Private Limited Extended release compositions comprising tolterodine
WO2011061616A2 (en) 2009-11-23 2011-05-26 Micro Labs Limited Extended release compositions containing tolterodine and process for preparing the same
WO2011095388A1 (en) 2010-02-04 2011-08-11 Synthon Bv Tolterodine bead
GB2479213B (en) 2010-04-01 2013-07-10 Theravida Inc Pharmaceutical formulations for the treatment of overactive bladder
RU2671575C2 (ru) 2011-05-10 2018-11-02 Теравида, Инк. Применение солифенацина и стимуляторов слюноотделения в лечении гиперактивного мочевого пузыря
CN103211784B (zh) * 2012-01-18 2017-07-11 北京天衡药物研究院有限公司 酒石酸托特罗定膜控缓释微丸胶囊
TW201422254A (zh) 2012-11-21 2014-06-16 Ferring Bv 用於速釋及延釋的組成物
DK3405191T3 (da) 2016-01-20 2025-05-19 Theravida Inc Sammensætninger til anvendelse ved behandling af hyperhidrose

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE2061C1 (ru) † 1890-01-25
SE8800207D0 (sv) 1988-01-22 1988-01-22 Kabivitrum Ab Nya aminer, deras anvendning och framstellning
SE9203318D0 (sv) 1992-11-06 1992-11-06 Kabi Pharmacia Ab Novel 3,3-diphenylpropylamines, their use and preparation
US6274171B1 (en) † 1996-03-25 2001-08-14 American Home Products Corporation Extended release formulation of venlafaxine hydrochloride
JP2000515525A (ja) 1996-07-19 2000-11-21 アベーグ，グンナー 尿と胃腸の疾患の治療におけるｓ（―）―トルテロジン
KR20000057548A (ko) 1996-12-13 2000-09-25 알프레드 엘. 미첼슨 광학적 전송물질 및 결합재
SE9803871D0 (sv) † 1998-11-11 1998-11-11 Pharmacia & Upjohn Ab Therapeutic method and formulation
SI1039882T1 (sl) * 1998-08-27 2011-01-31 Pfizer Health Ab Terapevtska formulacija za dajanje tolterodina s kontroliranim sproščanjem
DE19901692C2 (de) † 1999-01-18 2002-06-20 Gruenenthal Gmbh Verfahren zur Herstellung von Pellets mit einem Gehalt von bis zu 90 Gew.% eines pharmazeutischen Wirkstoffes
KR100838930B1 (ko) * 1999-11-11 2008-06-16 화이자 헬스 에이비 톨테로딘을 포함하는 약학 제제 및 이의 용도
SE9904850D0 (sv) 1999-12-30 1999-12-30 Pharmacia & Upjohn Ab Novel process and intermediates
IN191835B (ru) 2001-08-03 2004-01-10 Ranbaxy Lab Ltd
US20030185882A1 (en) * 2001-11-06 2003-10-02 Vergez Juan A. Pharmaceutical compositions containing oxybutynin
WO2003053428A1 (en) * 2001-12-20 2003-07-03 Pharmacia Corporation Controlled release dosage form having improved drug release properties
KR100540035B1 (ko) † 2002-02-01 2005-12-29 주식회사 태평양 다단계 경구 약물 방출 제어 시스템
US7005449B2 (en) 2002-04-23 2006-02-28 Pharmacia & Upjohn Company Tolterodine salts
CN1150160C (zh) 2002-04-29 2004-05-19 上海医药工业研究院 L－酒石酸托特罗定的合成方法
EP1635795A1 (en) 2003-05-30 2006-03-22 Ranbaxy Laboratories, Ltd. Controlled release pharmaceutical compositions of tolterodine and processes for their preparation

Also Published As

Publication number Publication date
NO20071299L (no) 2007-05-29
WO2006021425A1 (en) 2006-03-02
EP1629834A1 (en) 2006-03-01
DE602005027469D1 (de) 2011-05-26
ATE505187T1 (de) 2011-04-15
EA200700484A1 (ru) 2007-10-26
EP1781275A1 (en) 2007-05-09
EP1781275B1 (en) 2011-04-13
EP1781275B2 (en) 2014-04-16
EP1964553A1 (en) 2008-09-03

Similar Documents

Publication Publication Date Title
NO20071299L (no) Vedvarende frigivelse farmasoytisk sammensetning av tolterodine
TW200716646A (en) (S)-N-methylnaltrexone
MX348525B (es) Proceso para producir poxvirus y composiciones de poxvirus.
CY1111470T1 (el) Νεες φαρμακευτικες συνθεσεις που περιεχουν φλιβανσερινη πολυμορφη α
UA96449C2 (en) Stable laquinimod preparations
JO2973B1 (en) Fumarate salt for (alpha-beta-R) -6-bromo-alpha-[2- (methylamino) ethyl-2-methoxy-alpha-1-naphthalenyl-beta-phenyl-3-quinoline ethanol
IL183360A (en) 12-aryl prostaglandin analogs, compositions comprising them and their use in the preparation of medicaments
MX2007010996A (es) Nuevas composiciones de liposomas.
TW200619220A (en) New hydrates and polymorphs of 4-[[(7r)-8-cyclopentyl-7-ethyl-5, 6, 7, 8-tetrahydro-5-methyl-6-oxo-2-pteridinyl]amino]-3-mithoxy-n-(1-methyl-4-piperidinyl)-benzamide, process for their manufacture and their use as medicament
MX2009006345A (es) Compuestos utiles como inhibidores de proteina cinasa.
TW200621737A (en) 2-carbamide-4-phenylthiazole derivatives, preparation thereof and therapeutic use thereof
UA103500C2 (ru) Сульфоксиминзамещенные анилинопиримидиновые производные как cdk-ингибиторы, их получение и применение как лекарственных средств
TW200621765A (en) Substituted phenylaminothiazoles and their use
IL198845A (en) An extended-release peptide preparation, a process for its preparation and use for drug preparation
WO2007144169A3 (en) Entacapone-derivatives
DE502005005636D1 (en) Spirocyclische cyclohexan-derivate
UA92894C2 (ru) Способ приготовления и применения композиции адсорбента фосфата, адсорбент фосфата, композиция адсорбента фосфата
MX347237B (es) Formulaciones farmaceuticas y usos de las mismas en el tratamiento de la disfuncion sexual femenina.
WO2011047837A3 (de) Schmelzgranuliertes cinacalcet
WO2010044097A3 (en) Novel dosage form of paliperidone and process for preparing the same
EA200700637A1 (ru) Соли донепезила, подходящие для получения фармацевтических композиций
TW200612922A (en) Inhibitors of hsp90
CR7271A (es) Formulaciones farmaceuticas novedosas a base de melatonina y compuestos similares para su uso en transtornos del sueno
UA94042C2 (ru) Применение агомелатина в получении лекарственных средств, предназначенных для лечения синдрома смита-магениса
GB2443377A (en) Anti-malarial composition comprising artesunate and lumefantrine